Commercial production by CDMO Lonza follows the recent US FDA nod for Portola’s Prior Approval Supplement (PAS) for recombinant factor Xa product Andexxa. FDA approval of Portola Pharmaceuticals, Inc.’s Prior Approval Supplement (PAS) for second-generation Andexxa follows collaboration with Lonza Pharma & Biotech to develop the manufacturing process The production of this second-generation Andexxa [coagulation factor Xa (recombinant), inactivated] has now begun, with Swiss contract development and manufacturing organization (CDMO) Lonza supplying the recombinant coagulation factor from its Porriño, Spain…

GE Healthcare will equip G-CON’s prefabricated cleanrooms with its cell therapy and viral vector technologies in the latest expansion of its partnership. The collaboration aims to incorporate GE Healthcare’s cell therapy and viral vector technologies and process design within G-CON’s prefabricated flexible cleanrooms (known as ‘PODs’) in efforts to speed up and offer flexibility to customers’ advanced therapy projects. “This collaboration is unique because it provides our customers with an entire cleanroom infrastructure from a single source and will improve…